Literature DB >> 27825428

Diagnostic and Therapeutic Strategies for Prostate Cancer.

Mary Nguyen-Nielsen1, Michael Borre2.   

Abstract

Prostate cancer (PC) is a major disease that affects men's health worldwide. It is the second most common form of cancer in men, surpassed only by nonmelanoma skin cancers such as basal and squamous cell carcinomas. Diagnostic strategies with population screening for prostate cancer using prostate-specific antigen (PSA) has been surrounded with controversy and debated intensively ever since the PSA protein was first purified in 1979 by Wang et al. At the same time, advances in diagnostic imaging, surgery, radiation, and chemotherapy have increased the opportunity to effectively diagnose, treat, and manage PC. Given the sheer burden of PC disease in Denmark and worldwide, new and innovative strategies for cancer diagnosis and care are needed. This article is a short review of current diagnostic and therapeutic strategies for the care and management of prostate cancer in Denmark.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27825428     DOI: 10.1053/j.semnuclmed.2016.07.002

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  24 in total

Review 1.  The role of ferroptosis in prostate cancer: a novel therapeutic strategy.

Authors:  Yue Wang; Yifan Ma; Kui Jiang
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-09-02       Impact factor: 5.455

Review 2.  Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives.

Authors:  Felice Crocetto; Gianluca Russo; Erika Di Zazzo; Pasquale Pisapia; Benito Fabio Mirto; Alessandro Palmieri; Francesco Pepe; Claudio Bellevicine; Alessandro Russo; Evelina La Civita; Daniela Terracciano; Umberto Malapelle; Giancarlo Troncone; Biagio Barone
Journal:  Cancers (Basel)       Date:  2022-07-04       Impact factor: 6.575

Review 3.  Recent Advances and Perspectives on the Health Benefits of Urolithin B, A Bioactive Natural Product Derived From Ellagitannins.

Authors:  Peng Chen; Zhiei Guo; Fuchao Chen; Yue Wu; Benhong Zhou
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

Review 4.  Hypoxia signaling in human health and diseases: implications and prospects for therapeutics.

Authors:  Zhen Luo; Mingfu Tian; Ge Yang; Qiaoru Tan; Yubing Chen; Geng Li; Qiwei Zhang; Yongkui Li; Pin Wan; Jianguo Wu
Journal:  Signal Transduct Target Ther       Date:  2022-07-07

Review 5.  Prostate cancer.

Authors:  Richard J Rebello; Christoph Oing; Karen E Knudsen; Stacy Loeb; David C Johnson; Robert E Reiter; Silke Gillessen; Theodorus Van der Kwast; Robert G Bristow
Journal:  Nat Rev Dis Primers       Date:  2021-02-04       Impact factor: 52.329

6.  Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.

Authors:  Ying-Li Lin; Yan-Li Li; Jian-Guo Ma
Journal:  Med Sci Monit       Date:  2017-10-13

7.  Atrial Fibrillation and Risk of Cancer: A Danish Population-Based Cohort Study.

Authors:  Nicklas Vinter; Amanda M S Christesen; Morten Fenger-Grøn; Anne Tjønneland; Lars Frost
Journal:  J Am Heart Assoc       Date:  2018-09-04       Impact factor: 5.501

Review 8.  Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives.

Authors:  Malwina Czerwińska; Aleksander Bilewicz; Marcin Kruszewski; Aneta Wegierek-Ciuk; Anna Lankoff
Journal:  Molecules       Date:  2020-04-10       Impact factor: 4.411

9.  Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.

Authors:  Yue Gu; Mengxia Xue; Qizhi Wang; Xiaodan Hong; Xinyu Wang; Fang Zhou; Jianguo Sun; Guangji Wang; Ying Peng
Journal:  Int J Mol Sci       Date:  2021-12-08       Impact factor: 5.923

10.  Association between periodontal disease and prostate cancer: a systematic review and meta-analysis.

Authors:  Y Wei; Y Zhong; Y Wang; R Huang
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.